The country's drug regulator on Tuesday allowed Serum Institute of India (SII) to resume trials of the AstraZeneca-Oxford vaccine candidate, Covishield, revoking its earlier order suspending new recruitments for phase two and three tests.
The resumption of trails was allowed after the vaccine maker submitted recommendations of the Data Safety Monitoring Board (DSMB), the UK, and DSMB, India. Giving permission, Drugs Controller General of India (DCGI) V G Somani said that SII’s reply had been "carefully examined".
The regulator, earlier, had asked SII to suspend volunteer recruitments for phase two and three clinical trials of Covishield and directed the firm